European Respiratory Society Annual Congress 2012 Abstract Number: 2861 Publication Number: P745 Abstract Group: 1.6. General Practice and Primary Care Keyword 1: COPD - management Keyword 2: Primary care Keyword 3: Treatments Title: Management of COPD in a primary care in Bahia, northeast of Brazil Prof. Charleston 7686 Ribeiro Pinto
[email protected] 1,2,3, Ms. Láira 7687 Yamamura
[email protected] 1,2, Mr. Fábio Fernando 7688 Oliveira
[email protected] 2, Ms. Aramis 7689 Alcântara
[email protected] 1,2, Prof. Lindemberg 7690 Costa
[email protected] 1, Prof. Dr Giselia 7696 Souza
[email protected] 1 and Prof. Dr Antônio Carlos 30645 Lemos
[email protected] MD 1,2. 1 Department of Pneumology, University Federal of Bahia, Salvador, Bahia, Brazil, 40110-910 ; 2 Respira Bahia Program, Bahia State Departments of Health, Salvador, Bahia, Brazil, 41150-450 and 3 College of Pharmacy, State University of the South West of Bahia, Jequié, Bahia, Brazil, 45083-900 . Body: Introduction: Deficiencies in management of COPD is responsible for the disease exacerbations increased numbers. Objective: To evaluate the current pharmacological treatment of the COPD in a primary health care center and to compare as recommended by GOLD 2010 guidelines. Methods: A prospective cross-sectional survey was performed with COPD outpatients. The patients were recruited as a sequential sample from September 2010 until August 2011, in the primary center of Bahia State Health Department. Results: In total, the sample was 363 outpatients (245 male, aged from 65.3 ± 11.4 yrs) with moderate to very severe disease status (FEV1 40.6 ± 14.4% pred). Of these, 263 (72.4%) patients were using any drug to treatment of COPD. The prescriptions according to GOLD stages are documented in the table below. Under-prescribing with bronchodilators long acting agents, particularly long-acting anticholinergic were recommended in 76% of the cases and 16.8% were using. Inhaled steroids were over-prescribed (recommended in 55%; taken by 77%). The overall analysis showed that only 98 (37.2%) patients were under treatment according with GOLD guidelines. Table. Drug prescriptions stratified according GOLD stages and divided for drug classes Stage II
Stage III
Stage IV
All
(n=61)
(n=130)
(n=72)
(n=263)
Short-acting β2-agonist
39,3
56,9
54,1
52,0
Short-acting anticholinergic
9,8
16,9
12,5
14,0
Long-acting β2-agonist
75.4
70.0
63.8
69.5
Inhaled steroid
85.2
77.6
70.8
77.5
Drug prescriptions, %
Long-acting anticholinergic
11.4
12.3
15.2
12.9
Methylxanthine
13.1
9.2
20.8
13.3
Conclusions: Our study has demonstrated that COPD patients in the primary care in Bahia-Brazil did not receive the pharmacological treatment recommended.
